Clinical trials show a pancreatic cancer drug nearly doubles survival, a head-and-neck therapy shrinks tumors, and new research explains drug resistance. Cancer mortality is falling in the US and UK.
Eli Lilly's Retevmo met the primary endpoint in a Phase III lung cancer trial, Merck discontinued its TROP2 ADC MK-6837, and a Tango/Revolution combination showed benefit in pancreatic cancer.
An experimental pill called daraxonrasib nearly doubled survival for patients with advanced pancreatic cancer in a clinical trial, marking a significant advance for a deadly disease. The drug targets a mutated protein previously considered "undruggable" and reduced the risk of death by 60% compared to chemotherapy.
The global pancreatic cancer precision medicine market is projected to grow from US$ 610 million in 2024 to US$ 2,467.83 million by 2033 at a 16.8% CAGR, driven by advances in targeted therapies, genomic diagnostics, and liquid biopsies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07692750 |
IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT06278454 |
Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases |
RECRUITING | PHASE1 |
| NCT04104672 |
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT04098081 |
1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma |
ACTIVE_NOT_RECRUITING | PHASE2 |
